BR112022020193A2 - Métodos de tratamento de infecções por sars-cov-2 - Google Patents

Métodos de tratamento de infecções por sars-cov-2

Info

Publication number
BR112022020193A2
BR112022020193A2 BR112022020193A BR112022020193A BR112022020193A2 BR 112022020193 A2 BR112022020193 A2 BR 112022020193A2 BR 112022020193 A BR112022020193 A BR 112022020193A BR 112022020193 A BR112022020193 A BR 112022020193A BR 112022020193 A2 BR112022020193 A2 BR 112022020193A2
Authority
BR
Brazil
Prior art keywords
cov
sars
infections
methods
treatment
Prior art date
Application number
BR112022020193A
Other languages
English (en)
Inventor
Hepner Adrian
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of BR112022020193A2 publication Critical patent/BR112022020193A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MÉTODOS DE TRATAMENTO DE INFECÇÕES POR SARS-COV-2. A divulgação é direcionada a métodos de uso de dantroleno ou uma pró-droga de dantroleno, ou um sal farmaceuticamente aceitável deste, para tratar infecções por COVID-19 e SARS-CoV-2.
BR112022020193A 2020-04-10 2021-04-08 Métodos de tratamento de infecções por sars-cov-2 BR112022020193A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063008486P 2020-04-10 2020-04-10
US202063062599P 2020-08-07 2020-08-07
PCT/US2021/026302 WO2021207443A1 (en) 2020-04-10 2021-04-08 Methods of treating sars-cov-2 infections

Publications (1)

Publication Number Publication Date
BR112022020193A2 true BR112022020193A2 (pt) 2022-11-22

Family

ID=75787221

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020193A BR112022020193A2 (pt) 2020-04-10 2021-04-08 Métodos de tratamento de infecções por sars-cov-2

Country Status (11)

Country Link
US (1) US20230144719A1 (pt)
EP (1) EP4132518A1 (pt)
JP (1) JP2023521163A (pt)
KR (1) KR20230002371A (pt)
CN (1) CN115361947A (pt)
AU (1) AU2021253866A1 (pt)
BR (1) BR112022020193A2 (pt)
CA (1) CA3174710A1 (pt)
IL (1) IL296517A (pt)
MX (1) MX2022012705A (pt)
WO (1) WO2021207443A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3697779A1 (en) 2017-10-20 2020-08-26 Eagle Research Labs Limited Dantrolene prodrugs and methods of their use
WO2019095056A1 (en) * 2017-11-14 2019-05-23 University Health Network Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions

Also Published As

Publication number Publication date
EP4132518A1 (en) 2023-02-15
AU2021253866A1 (en) 2022-10-20
MX2022012705A (es) 2022-11-07
WO2021207443A1 (en) 2021-10-14
US20230144719A1 (en) 2023-05-11
KR20230002371A (ko) 2023-01-05
CA3174710A1 (en) 2021-10-14
JP2023521163A (ja) 2023-05-23
CN115361947A (zh) 2022-11-18
IL296517A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EA202191177A1 (ru) 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8
EP4331677A3 (en) Methods of treating feline coronavirus infections
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
BR112019002576A2 (pt) composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
BR112021026445A2 (pt) Composições e métodos para tratar distúrbios de cns
TR201905233T4 (tr) Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
BR112018016349A2 (pt) métodos para tratamento e profilaxia de hiv e aids
BR112022016360A2 (pt) Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
DOP2021000039A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
BR112022013480A2 (pt) Métodos de tratamento de coronavírus
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112023025789A2 (pt) Nitroxolina para uso no tratamento de neurofibroma cutâneo
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
BR112019006174A2 (pt) proteina terapêutica
EA201990109A1 (ru) Митохондриальные ингибиторы для лечения пролиферативных нарушений
BR112022020193A2 (pt) Métodos de tratamento de infecções por sars-cov-2
BR112021017198A2 (pt) Uso de vibegron para tratar bexiga hiperativa
AR110913A1 (es) Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas